JP2022545737A - 血管疾患を処置する組成物および方法 - Google Patents

血管疾患を処置する組成物および方法 Download PDF

Info

Publication number
JP2022545737A
JP2022545737A JP2022513534A JP2022513534A JP2022545737A JP 2022545737 A JP2022545737 A JP 2022545737A JP 2022513534 A JP2022513534 A JP 2022513534A JP 2022513534 A JP2022513534 A JP 2022513534A JP 2022545737 A JP2022545737 A JP 2022545737A
Authority
JP
Japan
Prior art keywords
meso
cells
vpcs
hsa
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545737A5 (https=
Inventor
マリア ミロツォウ
ヌタン プラセイン
アムリタ シン
ロバート ランザ
Original Assignee
アステラス インスティテュート フォー リジェネラティブ メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アステラス インスティテュート フォー リジェネラティブ メディシン filed Critical アステラス インスティテュート フォー リジェネラティブ メディシン
Publication of JP2022545737A publication Critical patent/JP2022545737A/ja
Publication of JP2022545737A5 publication Critical patent/JP2022545737A5/ja
Priority to JP2025158999A priority Critical patent/JP2026001090A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022513534A 2019-08-28 2020-08-27 血管疾患を処置する組成物および方法 Pending JP2022545737A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025158999A JP2026001090A (ja) 2019-08-28 2025-09-25 血管疾患を処置する組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892724P 2019-08-28 2019-08-28
US62/892,724 2019-08-28
PCT/US2020/048076 WO2021041591A1 (en) 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025158999A Division JP2026001090A (ja) 2019-08-28 2025-09-25 血管疾患を処置する組成物および方法

Publications (2)

Publication Number Publication Date
JP2022545737A true JP2022545737A (ja) 2022-10-28
JP2022545737A5 JP2022545737A5 (https=) 2023-09-05

Family

ID=72428364

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513534A Pending JP2022545737A (ja) 2019-08-28 2020-08-27 血管疾患を処置する組成物および方法
JP2025158999A Pending JP2026001090A (ja) 2019-08-28 2025-09-25 血管疾患を処置する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025158999A Pending JP2026001090A (ja) 2019-08-28 2025-09-25 血管疾患を処置する組成物および方法

Country Status (13)

Country Link
US (1) US20220288131A1 (https=)
EP (1) EP4022038A1 (https=)
JP (2) JP2022545737A (https=)
KR (1) KR20220049618A (https=)
CN (1) CN115003794A (https=)
AU (1) AU2020337444A1 (https=)
BR (1) BR112022003659A2 (https=)
CA (1) CA3151636A1 (https=)
IL (1) IL290891A (https=)
MX (1) MX2022002418A (https=)
PH (1) PH12022550392A1 (https=)
TW (1) TW202122573A (https=)
WO (1) WO2021041591A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
EP4372079A4 (en) * 2021-07-15 2025-07-30 Astellas Pharma Inc PERICYTE-LIKE CELLS EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AT A HIGH LEVEL
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
US20240228975A9 (en) * 2022-07-19 2024-07-11 Lung Biotechnology Pbc Methods for Differentiating Endothelial Cells
CN118177150B (zh) * 2024-04-15 2024-12-03 中国医学科学院医学实验动物研究所 遗传多样性高血压小鼠模型的建立与基因转录调控分析

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017014165A1 (ja) * 2015-07-17 2017-01-26 国立大学法人京都大学 血管内皮細胞の誘導方法
JP2017023019A (ja) * 2015-07-17 2017-02-02 国立大学法人京都大学 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
JP2018505685A (ja) * 2015-02-20 2018-03-01 ウィスコンシン アラムニ リサーチ ファンデーション 動脈内皮細胞集団の生成
JP2019528057A (ja) * 2016-08-10 2019-10-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インビボで血管形成能を有する中胚葉細胞および／または血管内皮コロニー形成細胞様細胞を作製する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434527A (zh) 2006-04-14 2017-02-22 安斯泰来再生医药协会 血管瘤集落形成细胞
CA3186451A1 (en) * 2008-05-06 2009-11-12 Astellas Institute For Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
WO2010001375A1 (en) * 2008-06-30 2010-01-07 University College Cork, National University Of Ireland, Cork Primitive vascular progenitor cells and uses thereof
US20110305672A1 (en) * 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20140045265A1 (en) * 2011-02-16 2014-02-13 Salk Institute For Biological Studies Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors
RU2618871C2 (ru) * 2011-06-09 2017-05-11 Ф. Хоффманн-Ля Рош Аг Способ дифференциации плюрипотентных стволовых клеток в клетки сосудистого русла
WO2013069661A1 (ja) * 2011-11-08 2013-05-16 国立大学法人名古屋大学 iPS細胞由来血管前駆細胞シート及びその作製方法
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
WO2015153586A1 (en) * 2014-03-31 2015-10-08 The Johns Hopkins University Pluripotent stem cell therapies for ischemic retinopathies
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
WO2016185457A1 (en) * 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
WO2019152483A1 (en) * 2018-01-30 2019-08-08 University Of Georgia Research Foundation, Inc. Methods for vascular construction and products therefrom

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505685A (ja) * 2015-02-20 2018-03-01 ウィスコンシン アラムニ リサーチ ファンデーション 動脈内皮細胞集団の生成
WO2017014165A1 (ja) * 2015-07-17 2017-01-26 国立大学法人京都大学 血管内皮細胞の誘導方法
JP2017023019A (ja) * 2015-07-17 2017-02-02 国立大学法人京都大学 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
JP2019528057A (ja) * 2016-08-10 2019-10-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インビボで血管形成能を有する中胚葉細胞および／または血管内皮コロニー形成細胞様細胞を作製する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOMICROFLUIDICS, vol. 10, 014106, JPN6024043365, 2016, pages 1 - 014106, ISSN: 0005773333 *
CELL RESEARCH, vol. 24, JPN6024043364, 2014, pages 820 - 841, ISSN: 0005773332 *
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A, vol. VOL 104A, ISSUE 3, JPN6024043363, 2016, pages 678 - 687, ISSN: 0005773331 *
NATURE BIOTECHNOLOGY, vol. 28, no. 2, JPN6024043362, 2010, pages 161 - 166, ISSN: 0005773330 *

Also Published As

Publication number Publication date
KR20220049618A (ko) 2022-04-21
TW202122573A (zh) 2021-06-16
BR112022003659A2 (pt) 2022-05-24
WO2021041591A1 (en) 2021-03-04
CA3151636A1 (en) 2021-03-04
AU2020337444A1 (en) 2022-03-24
MX2022002418A (es) 2022-03-22
PH12022550392A1 (en) 2022-12-19
CN115003794A (zh) 2022-09-02
IL290891A (en) 2022-04-01
JP2026001090A (ja) 2026-01-06
US20220288131A1 (en) 2022-09-15
EP4022038A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
JP7333271B2 (ja) 心筋細胞の成熟および生着を増強するための方法および組成物
JP2022545737A (ja) 血管疾患を処置する組成物および方法
JP2024050597A (ja) 免疫改変された多能性細胞から分化させた細胞
CA2718032C (en) Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications
EP2900069B1 (en) Differentiation of human ips cells to human alveolar type ii via definitive endoderm
JP7723482B2 (ja) 網膜色素上皮細胞集団の評価法
JP2025111765A (ja) Ｒｐｅ細胞集団およびそれを作製する方法
AU2011299327B2 (en) Tissue-specific differentiation matrices and uses thereof
CN111630155B (zh) 胰岛细胞制备性组合物和使用方法
US20120295347A1 (en) Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells
AU2018217992A1 (en) Photoreceptor cells for the treatment of retinal diseases
WO2014011095A1 (en) Derivation and self-renewal of isi1+ cells and uses thereof
US20250019652A1 (en) Production method for sheet-like retinal tissue
RU2843942C2 (ru) Композиции и способы лечения сосудистых заболеваний
US20110076254A1 (en) Porous scaffolds for stem cell renewal
HK40114369A (en) Production method for sheet-like retinal tissue
IL193947A (en) Cells cultured as cd31brigi: it, a method for stimuli to differentiate into a congenital / precursor cell population (pcp), use of the same drug preparation population, and implantation device that includes it

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417